Quantitative Sensory Test for the Detection of Diabetic Peripheral Neuropathy

Lee, Eun Woo; Kang, Soo Yong; Jang, Eui Chan; Jin, Whui Jae; Seo, Kyung Mook

doi:10.4055/jkoa.1995.30.4.823

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, these devices have not gained widespread usage in primary care practice. Some of the factors that may be limiting their use in routine clinical settings include their size, the requirement for a dedicated space and uninterrupted power supply, and the time needed for the examination [ 28 , 29 ].…”

Section: Introductionmentioning

confidence: 99%

Assessment of the diagnostic accuracy of Vibrasense compared to a biothesiometer and nerve conduction study for screening diabetic peripheral neuropathy

Sharma K. N,

Kumar H

2023

Journal of Foot and Ankle Research

View full text Add to dashboard Cite

Aims Peripheral neuropathy is a common microvascular complication in diabetes and a risk factor for the development of diabetic foot ulcers and amputations. Vibrasense (Ayati Devices) is a handheld, battery-operated, rapid screening device for diabetic peripheral neuropathy (DPN) that works by quantifying vibration perception threshold (VPT). In this study, we compared Vibrasense against a biothesiometer and nerve conduction study for screening DPN. Methods A total of 562 subjects with type 2 diabetes mellitus underwent neuropathy assessments including clinical examination, 10-g monofilament test, VPT evaluation with Vibrasense and a standard biothesiometer. Those with an average VPT ≥ 15 V with Vibrasense were noted to have DPN. A subset of these patients (N = 61) underwent nerve conduction study (NCS). Diagnostic accuracy of Vibrasense was compared against a standard biothesiometer and abnormal NCS. Results Average VPTs measured with Vibrasense had a strong positive correlation with standard biothesiometer values (Spearman’s correlation 0.891, P < 0.001). Vibrasense showed sensitivity and specificity of 87.89% and 86.81% compared to biothesiometer, and 82.14% and 78.79% compared to NCS, respectively. Conclusions Vibrasense demonstrated good diagnostic accuracy for detecting peripheral neuropathy in type 2 diabetes and can be an effective screening device in routine clinical settings. Trial registration Clinical trials registry of India (CTRI/2022/11/047002). Registered 3 November 2022. https://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=76167.

show abstract

Section: Introductionmentioning

confidence: 99%